By Gilang Cahya 
In a groundbreaking discovery, researchers have unveiled a sophisticated survival mechanism employed by bowel cancer cells, revealing their ability to strategically regulate their own growth through a dynamic genetic "on-off switch." This pivotal finding, observed for the first time by a collaborative team from University College London (UCL) and University Medical Center Utrecht, challenges the long-held belief that the accumulation of genetic mutations in cancer is a purely random process. Instead, it suggests a deliberate and adaptive evolutionary strategy by tumors to maximize their chances of survival and proliferation.
Unraveling the Evolutionary Balancing Act of Cancer
For decades, the scientific community largely accepted that the vast number of genetic mutations found within cancer cells were a consequence of chance occurrences, accumulating over time. However, the new study, published in the prestigious journal Nature Genetics, provides compelling evidence that cancer cells actively navigate an intricate "evolutionary balancing act." This intricate dance involves the precise manipulation of DNA repair mechanisms, effectively acting as genetic switches that can either accelerate or decelerate tumor growth depending on what serves the cancer’s immediate evolutionary advantage.
The core of this discovery lies in the observation that mutations within DNA repair genes can be both deliberately introduced and subsequently reversed. This "flip-flop" capability allows cancer cells to transiently disable their DNA repair systems, leading to a rapid surge in mutations. This increased mutation rate can be advantageous in certain scenarios, such as evading the body’s immune surveillance by becoming more genetically distinct from healthy cells. However, this unrestrained mutation also carries risks, including triggering an immune response. Consequently, the research indicates that cancer cells can then "switch" these DNA repair mechanisms back on, selectively repairing critical parts of their genome to ensure their own survival and avoid attracting undue attention from the immune system.
The Significance of DNA Repair Genes in Cancer Development
Cancer, at its fundamental level, is a genetic disease driven by alterations in our DNA. Throughout life, DNA damage is a constant phenomenon, occurring naturally through cellular processes and being exacerbated by environmental factors like radiation and certain chemicals. To combat this pervasive threat, cells have evolved sophisticated repair systems to maintain the integrity of their genetic code. However, when mutations accumulate in genes that are crucial for cell growth regulation or DNA repair, the foundation for tumor development is laid.
Bowel cancer, also known as colorectal cancer, is a significant public health concern globally. In the United Kingdom, it stands as the fourth most common cancer, with an estimated 42,900 new cases diagnosed annually. While historically considered a disease predominantly affecting older individuals, recent decades have witnessed a concerning increase in cases among those under the age of 50, prompting intensified research into its underlying causes and progression.
Disruptions to DNA repair mechanisms are recognized as a major contributor to elevated cancer risk. Approximately 20% of bowel cancers, specifically those classified as mismatch repair deficient (MMRd), are directly linked to mutations in genes responsible for repairing errors during DNA replication. While disabling these repair mechanisms can facilitate tumor initiation and growth, it is not without its drawbacks for the cancer. The very process that allows for rapid mutation accumulation also increases the likelihood that the resulting genetic alterations will be recognized by the body’s immune system, potentially triggering an attack on the tumor.
A Collaborative Effort: Unveiling the "Genetic Switch"
The research team, comprising experts from UCL and University Medical Center Utrecht, embarked on a comprehensive analysis to understand how tumors balance the need for genetic variation with the imperative to evade immune detection. Dr. Marnix Jansen, a senior author of the study from the UCL Cancer Institute and UCLH, explained the underlying hypothesis: "Cancer cells need to acquire certain mutations to circumvent mechanisms that preserve our genetic code. But if a cancer cell acquires too many mutations, it is more likely to attract the attention of the immune system, because it’s so different from a normal cell. We predicted that understanding how tumors exploit faulty DNA repair to drive tumor growth—whilst simultaneously avoiding immune detection—might help explain why the immune system sometimes fails to control cancer development."
To investigate this, researchers meticulously analyzed the whole genome sequences of 217 MMRd bowel cancer samples from the UK’s 100,000 Genomes Project database. Their objective was to identify any correlations between the total number of mutations present in a tumor and specific genetic alterations within key DNA repair genes.
Identifying Key Genes and the "Flip-Flop" Mechanism
The rigorous analysis revealed a striking correlation: mutations in the MSH3 and MSH6 genes, both critical components of the DNA mismatch repair system, were consistently associated with an overall high volume of mutations within the cancer cells. This observation provided the crucial evidence supporting the existence of the proposed "flip-flop" mechanism.
To validate this theory, the researchers employed sophisticated laboratory models. They cultivated complex three-dimensional cell cultures, known as organoids, derived directly from patient tumor samples. These organoids mimicked the behavior of the original tumors, allowing the scientists to observe and confirm how mutations in the MSH3 and MSH6 genes acted as a "genetic switch," controlling the rate of mutation accumulation.
Dr. Suzanne van der Horst from University Medical Center Utrecht elaborated on the findings: "Our study reveals that DNA repair mutations in the MSH3 and MSH6 genes act as a genetic switch that cancers exploit to navigate an evolutionary balancing act. On one hand, these tumours roll the dice by turning off DNA repair to escape the body’s defence mechanisms. While this unrestrained mutation rate kills many cancer cells, it also produces a few ‘winners’ that fuel tumour development."
She further highlighted the innovative nature of this discovery: "The really interesting finding from our research is what happens afterwards. It seems the cancer turns the DNA repair switch back on to protect the parts of the genome that they too need to survive and to avoid attracting the attention of the immune system. This is the first time that we’ve seen a mutation that can be created and repaired over and over again, adding it or deleting it from the cancer’s genetic code as required."
Repetitive DNA and Evolutionary Parallels
The specific DNA repair mutations implicated in this phenomenon occur within repetitive stretches of DNA. These regions consist of sequences where a single DNA base (adenine, thymine, cytosine, or guanine) is repeated numerous times. During cell division, errors can easily occur in these repetitive segments, such as the deletion or addition of a single base, leading to significant disruptions in gene function.
Dr. Hamzeh Kayhanian, the study’s first author from the UCL Cancer Institute and UCLH, emphasized the paradigm shift this research represents: "The degree of genetic disarray in a cancer was previously thought to be purely down to chance accumulation of mutations over many years. Our work shows that cancer cells covertly repurpose these repetitive tracts in our DNA as evolutionary switches to fine-tune how rapidly mutations accumulate in tumour cells."
Intriguingly, the researchers noted a parallel between this cancer mechanism and the evolution of antibiotic resistance in bacteria. "Interestingly, this evolutionary mechanism had previously been found as a key driver of bacterial treatment resistance in patients treated with antibiotics," Dr. Kayhanian added. "Like cancer cells, bacteria have evolved genetic switches which increase mutational fuel when rapid evolution is key, for example when confronted with antibiotics. Our work thus further emphasises similarities between evolution of ancient bacteria and human tumour cells, a major area of active cancer research."
Implications for Personalized Cancer Medicine
The implications of this discovery for the future of cancer treatment are profound. The ability to identify and understand these dynamic genetic switches could revolutionize how oncologists assess and manage individual patient cases. By gauging the activity of these DNA repair switches, clinicians may be able to predict the aggressiveness of a particular tumor and tailor treatment strategies accordingly.
For instance, a tumor with its DNA repair mechanisms deliberately switched off might indicate a higher potential for rapid adaptation and evasion of treatment, particularly immunotherapies. These cutting-edge treatments are designed to harness the patient’s immune system to fight cancer, and they often work best against tumors with a high mutation burden. Understanding if this burden is actively being manipulated by the cancer could inform treatment decisions.
A follow-up study is already in progress to investigate what happens to these DNA repair switches in patients undergoing cancer treatment. This research aims to shed light on how tumors adapt their mutational strategies in response to therapeutic interventions.
Dr. Hugo Snippert, another senior author from the University Medical Center Utrecht, articulated the forward-looking vision: "Overall our research shows that mutation rate is adaptable in tumours and facilitates their quest to obtain optimal evolutionary fitness. New drugs might look to disable this switch to drive effective immune recognition and, hopefully, produce better treatment outcomes for affected patients."
Funding and Future Directions
This significant research was made possible through generous funding from Cancer Research UK, the Rosetrees Trust, and Bowel Research UK.
Georgia Sturt, Research and Grants Manager at Bowel Research UK, commented on the impact of the findings: "Cancer’s evasion of immune system destruction is a key element of its ability to grow and spread. Understanding exactly how bowel cancers do this is crucial to optimising treatment for patients. Bowel Research UK are delighted that our funding has contributed to producing this exciting new data, and we look forward to seeing how these discoveries could change treatments for future patients."
The discovery of this genetic on-off switch represents a major leap forward in our understanding of cancer biology. It not only challenges long-standing assumptions but also opens up promising new avenues for developing more effective and personalized cancer therapies, offering renewed hope for patients battling this formidable disease. The ongoing research promises to further elucidate the intricate evolutionary strategies employed by cancer and pave the way for innovative treatment approaches.
